Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Vyne Therapeutics Inc (VYNE)

Vyne Therapeutics Inc (VYNE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
VYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update GlobeNewswire - Thu Nov 7, 7:00AM CST

VYNE : 2.50 (+4.60%)
VYNE Therapeutics (NASDAQ: VYNE) Shares Positive Preclinical Data for VYN201 as a Potential Treatment for Idiopathic Pulmonary Fibrosis Spotlight Growth - Wed Apr 19, 2023

VYNE Therapeutics, Inc. (NASDAQ: VYNE) is engaged as a clinical-stage biopharma company, which is focused on the research and development

VYNE : 2.50 (+4.60%)
Wall Street - NYSE Full View
Pre-Market Brief: Stocks Mostly Lower As Hawkish Fed Remarks Weigh On Sentiment, Powell Speech In Focus Barchart - Tue Jan 10, 2023

March S&P 500 futures (ESH23) are trending down -0.08% this morning after three major U.S. benchmark indices ended the regular session mixed following hawkish remarks from two U.S. Federal Reserve officials,...

ESH23 : 3,957.05s (-0.09%)
AAPL : 254.49 (+1.88%)
GOOGL : 191.41 (+1.54%)
MSFT : 436.60 (-0.10%)
NVDA : 134.70 (+3.08%)
OSH : 39.00 (+0.08%)
VYNE : 2.50 (+4.60%)
FRO : 13.38 (+0.30%)
BLI : 1.2000 (-5.88%)
WWW : 23.06 (+2.72%)
VYNE Therapeutics Announces Results from its Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis Globe Newswire - Wed Aug 10, 2022

BRIDGEWATER, N.J., Aug. 10, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company...

VYNE : 2.50 (+4.60%)
VYNE Therapeutics to Present at the B&T Cell-Mediated Autoimmune Disease Drug Development Conference Globe Newswire - Tue Jul 19, 2022

BRIDGEWATER, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company...

VYNE : 2.50 (+4.60%)
VYNE Therapeutics Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis Globe Newswire - Fri Jun 17, 2022

Top-line Efficacy Results Expected in Approximately 6 to 8 Weeks...

VYNE : 2.50 (+4.60%)
VYNE Therapeutics to Present at HC Wainwright & Co. Global Investment Conference Globe Newswire - Wed May 18, 2022

BRIDGEWATER, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company...

VYNE : 2.50 (+4.60%)
VYNE Hosting Key Opinion Leader Event on Novel InhiBET™ BET Inhibitor Platform Globe Newswire - Tue May 10, 2022

Webinar on Tuesday, May 17, 2022 at 10:00 a.m. ET...

VYNE : 2.50 (+4.60%)
VYNE Reports Positive Preclinical Data for Intra-Articular Injection of Pan-BET Inhibitor, VYN201, in an In Vivo Model of Rheumatoid Arthritis Globe Newswire - Wed Mar 30, 2022

VYN201 demonstrated statistically significant improvement in treatment response for both endpoints at 1mg/kg and 10mg/kg dosesVYN201 also demonstrated...

VYNE : 2.50 (+4.60%)
VYNE Therapeutics Reports Year-End 2021 Financial Results and Provides Corporate Update Globe Newswire - Thu Mar 17, 2022

FMX114 demonstrated preliminary clinical safety and pharmacokinetics in Phase 1b study VYN201 shows promising preclinical data in 3 well-established and...

VYNE : 2.50 (+4.60%)

Barchart Exclusives

Elon Musk Didn't Expect Tesla or SpaceX to be Succesful, But He Did It Because They "Were Important Enough to do Anyway" Barchart - 18 minutes ago
In a reflection on his entrepreneurial journey, tech magnate Elon Musk offered a glimpse into the mindset that led him to launch two of the world’s most groundbreaking ventures: Tesla and SpaceX. Speaking on his early years of founding these companies, Musk said, “I always have optimism, but I’m realistic.... Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot